DDInter1397 DDInter1828
Paroxetine is a selective serotonin reuptake inhibitor (SSRI) drug commonly known as Paxil. It has a variety of uses, including the treatment of anxiety disorders, major depression, posttraumatic stress disorder, and symptoms of menopause, among others. It was approved by the FDA in the early 1990s and marketed by SmithKline Beecham.[L7712,L7715] A unique feature of this drug is that it is highly potent and selective in its inhibition of serotonin reuptake and has little effect on other neurotransmitters. Because of its potent inhibition of serotonin reuptake, paroxetine is more likely to cause withdrawal effects upon cessation. Paroxetine is well tolerated in most patients with a similar adverse effect profile to other members of its drug class. The controlled release formulation was designed to decrease the likelihood of nausea that is sometimes associated with paroxetine.[L7700,L7742]
Tolbutamide is an oral antihyperglycemic agent used for the treatment of non-insulin-dependent diabetes mellitus (NIDDM). It is structurally similar to acetohexamide, chlorpropamide and tolazamide and belongs to the sulfonylurea class of insulin secretagogues, which act by stimulating β cells of the pancreas to release insulin. Sulfonylureas increase both basal insulin secretion and meal-stimulated insulin release. Medications in this class differ in their dose, rate of absorption, duration of action, route of elimination and binding site on their target pancreatic β cell receptor. Sulfonylureas also increase peripheral glucose utilization, decrease hepatic gluconeogenesis and may increase the number and sensitivity of insulin receptors. Sulfonylureas are associated with weight gain, though less so than insulin. Due to their mechanism of action, sulfonylureas may cause hypoglycemia and require consistent food intake to decrease this risk. The risk of hypoglycemia is increased in elderly, debilitated and malnourished individuals. Tolbutamide appears to be metabolized in the liver. Tolbutamide and its metabolites are excreted in urine (75-85%) and feces.
Paroxetine {u} (Compound) binds {v} (Gene) CYP2C8
CYP2C8 {u} (Gene) is bound by {v} (Compound) Tolbutamide
Paroxetine {u} (Compound) downregulates {v} (Gene) SUV39H1
SUV39H1 {u} (Gene) is upregulated by {v} (Compound) Tolbutamide
Paroxetine {u} (Compound) downregulates {v} (Gene) CCDC86
CCDC86 {u} (Gene) is downregulated by {v} (Compound) Tolbutamide
Paroxetine {u} (Compound) causes {v} (Side Effect) Erythema
Erythema {u} (Side Effect) is caused by {v} (Compound) Tolbutamide
Paroxetine {u} (Compound) binds {v} (Gene) CYP2C8
CYP2C8 {u} (Gene) is bound by {v} (Compound) Probenecid
Probenecid {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Tolbutamide
Paroxetine {u} (Compound) binds {v} (Gene) CYP2C9
CYP2C9 {u} (Gene) is bound by {v} (Compound) Glipizide
Glipizide {u} (Compound) resembles {v} (Compound) Tolbutamide
Paroxetine {u} (Compound) downregulates {v} (Gene) SUV39H1
SUV39H1 {u} (Gene) is upregulated by {v} (Compound) Trimipramine
Trimipramine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Tolbutamide
Paroxetine {u} (Compound) downregulates {v} (Gene) CCDC86
CCDC86 {u} (Gene) regulates {v} (Gene) PDHX
PDHX {u} (Gene) is upregulated by {v} (Compound) Tolbutamide
Paroxetine {u} (Compound) causes {v} (Side Effect) Erythema
Erythema {u} (Side Effect) is caused by {v} (Compound) Tolazamide
Tolazamide {u} (Compound) resembles {v} (Compound) Tolbutamide
Paroxetine {u} (Compound) upregulates {v} (Gene) TSC22D3
TSC22D3 {u} (Gene) is upregulated by {v} (Compound) Tolazamide
Tolazamide {u} (Compound) resembles {v} (Compound) Tolbutamide
Paroxetine (Compound) binds CYP2C8 (Gene) and CYP2C8 (Gene) is bound by Tolbutamide (Compound)
Paroxetine (Compound) downregulates SUV39H1 (Gene) and SUV39H1 (Gene) is upregulated by Tolbutamide (Compound)
Paroxetine (Compound) downregulates CCDC86 (Gene) and CCDC86 (Gene) is downregulated by Tolbutamide (Compound)
Paroxetine (Compound) causes Erythema (Side Effect) and Erythema (Side Effect) is caused by Tolbutamide (Compound)
Paroxetine (Compound) binds CYP2C8 (Gene) and CYP2C8 (Gene) is bound by Probenecid (Compound) and Probenecid may cause a moderate interaction that could exacerbate diseases when taken with Tolbutamide
Paroxetine (Compound) binds CYP2C9 (Gene) and CYP2C9 (Gene) is bound by Glipizide (Compound) and Glipizide (Compound) resembles Tolbutamide (Compound)
Paroxetine (Compound) downregulates SUV39H1 (Gene) and SUV39H1 (Gene) is upregulated by Trimipramine (Compound) and Trimipramine may cause a moderate interaction that could exacerbate diseases when taken with Tolbutamide
Paroxetine (Compound) downregulates CCDC86 (Gene) and CCDC86 (Gene) regulates PDHX (Gene) and PDHX (Gene) is upregulated by Tolbutamide (Compound)
Paroxetine (Compound) causes Erythema (Side Effect) and Erythema (Side Effect) is caused by Tolazamide (Compound) and Tolazamide (Compound) resembles Tolbutamide (Compound)
Paroxetine (Compound) upregulates TSC22D3 (Gene) and TSC22D3 (Gene) is upregulated by Tolazamide (Compound) and Tolazamide (Compound) resembles Tolbutamide (Compound)